Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

In the Archives

“Less Radical” podcast: Resistance to change, a data scandal

“Less Radical” is the story of Bernie Fisher, the surgeon-scientist who not only revolutionized breast cancer treatment, but also fundamentally changed the way we understand all cancers.

November 01, 2024

Vol.50 No.41

In Brief

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.

October 25, 2024

Vol.50 No.40

In Brief

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

In the Archives

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

YOU MAY BE INTERESTED IN

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

“Less Radical” podcast: Resistance to change, a data scandal

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

SU2C announces grants supporting research in six cancer types

Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

Renew today!

Subscriber content

Login